Spiro Rombotis
President and CEO,
Cyclacel Pharmaceuticals, Inc.
United States
Mr. Rombotis joined Cyclacel as its first CEO in 1997 and has over 37 years at three public biotechs and two pharmas. He participated in in-licensing, clinical development, regulatory approval, partnering and commercial launch of several drugs, mainly in inflammation and hematology/oncology, including Abelcet®, Evacet/Myocet®, ProHance®, Remicade® and Reopro®. Major functional roles included international operations and business development as Vice President at The Liposome Co. (subsequently acquired by Elan) and previously Vice President in the pharmaceuticals division of Bristol-Myers Squibb. He began his career in the early ’80s, after training at Novartis, as one of the first employees of Centocor (subsequently acquired by Johnson & Johnson). He holds an MBA and MPH (Hospital & Health Services Management) with honors, Kellogg School of Management, Northwestern University and a BA, Williams College. He serves on the Board of Trustees of BioNJ, the NJ biotech association.
Sessions
-
26-Feb-2024Cyclacel Pharmaceuticals, Inc.
)
){kind=logo}
)
){kind=logo}
){kind=logo}